Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Oct-Dec;4(4):175-81.
doi: 10.4103/2279-042X.167043.

A short review on structure and role of cyclic-3',5'-adenosine monophosphate-specific phosphodiesterase 4 as a treatment tool

Nahid Eskandari  1 , Omid Mirmosayyeb  2 , Gazaleh Bordbari  2 , Reza Bastan  3 , Zahra Yousefi  2 , Alireza Andalib  2
Affiliations
Review

A short review on structure and role of cyclic-3',5'-adenosine monophosphate-specific phosphodiesterase 4 as a treatment tool

Nahid Eskandari et al. J Res Pharm Pract. 2015 Oct-Dec.

Abstract

Cyclic nucleotide phosphodiesterases (PDEs) are known as a super-family of enzymes which catalyze the metabolism of the intracellular cyclic nucleotides, cyclic-3',5'-adenosine monophosphate (cAMP), and cyclic-3',5'-guanosine monophosphate that are expressed in a variety of cell types that can exert various functions based on their cells distribution. The PDE4 family has been the focus of vast research efforts over recent years because this family is considered as a prime target for therapeutic intervention in a number of inflammatory diseases such as asthma, chronic obstructive pulmonary disease, and rheumatoid arthritis, and it should be used and researched by pharmacists. This is because the major isoform of PDE that regulates inflammatory cell activity is the cAMP-specific PDE, PDE4. This review discusses the relationship between PDE4 and its inhibitor drugs based on structures, cells distribution, and pharmacological properties of PDE4 which can be informative for all pharmacy specialists.

Keywords: Cyclic-3’, 5’-adenosine monophosphate; inhibitors; phosphodiesterase; phosphodiesterase 4.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Diagram showing long (a), short (b) and super-short variants (c) of phosphodiesterase 4 generated by alternative splicing. UCR: Upstream conserved region; LR = Linker region
See this image and copyright information in PMC

References

    1. Guo L, Luo L, Ju R, Chen C, Zhu L, Li J, et al. Carboxyamidotriazole: A novel inhibitor of both cAMP-phosphodiesterases and cGMP-phosphodiesterases. Eur J Pharmacol. 2015;746:14–21. - PubMed
    1. Rickles RJ, Pierce LT, Giordano TP, 3rd, Tam WF, McMillin DW, Delmore J, et al. Adenosine A2A receptor agonists and PDE inhibitors: A synergistic multitarget mechanism discovered through systematic combination screening in B-cell malignancies. Blood. 2010;116:593–602. - PubMed
    1. Ahmad F, Murata T, Shimizu K, Degerman E, Maurice D, Manganiello V. Cyclic nucleotide phosphodiesterases: Important signaling modulators and therapeutic targets. Oral Dis. 2015;21:e25–50. - PMC - PubMed
    1. Chen X, Zhao X, Xiong Y, Liu J, Zhan CG. Fundamental reaction pathway and free energy profile for hydrolysis of intracellular second messenger adenosine 3’,5’-cyclic monophosphate (cAMP) catalyzed by phosphodiesterase-4. J Phys Chem B. 2011;115:12208–19. - PMC - PubMed
    1. Blaha M, Nemcova L, Prochazka R. Cyclic guanosine monophosphate does not inhibit gonadotropin-induced activation of mitogen-activated protein kinase 3/1 in pig cumulus-oocyte complexes. Reprod Biol Endocrinol. 2015;13:1. - PMC - PubMed